HealthCor Partners Fund II, L.P. 3
Accession 0000908662-18-000164
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 4:23 PM ET
Size
21.0 KB
Accession
0000908662-18-000164
Insider Transaction Report
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)- 37,892
Common Stock, par value $0.01 per share
- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)
- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)- 37,892
Common Stock, par value $0.01 per share
- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)
- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)
- 37,892
Common Stock, par value $0.01 per share
Series C Convertible Preferred Stock, par value $0.01
→ Common Stock (311,247 underlying)
Footnotes (3)
- [F1]Share amounts and conversion ratios reflect the 15-for-1 reverse stock split effected June 4, 2018.
- [F2]HealthCor Partners Fund II, L.P. ("HCPII Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCPII Fund may be deemed to be beneficially owned by HealthCor Partners II, L.P. ("HCP2LP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCP2LP. HealthCor Partners Management, L.P. ("HPMLP") serves as the investment manager to HCPII Fund, and HealthCor Partners Management GP, LLC ("HCPMGP") serves as the general partner of HPMLP. Jeffrey C. Lightcap, Arthur Cohen, and Joseph Healey are managing members of HCPMGP and HCPGP. Each reporting owner disclaims beneficial ownership of shares held by HCPII Fund except to the extent of any pecuniary interest therein.
- [F3]The shares were issued in connection with the Agreement and Plan of Merger, dated October 2, 2017, among ReShape Lifesciences Inc. (formerly EnteroMedics Inc., the "Company"), ReShape Medical, Inc. ("ReShape Medical"), and the other parties named therein (the "Merger Agreement"), pursuant to which the Company acquired ReShape Medical. Each share of Series C Convertible Preferred Stock issued under the Merger Agreement is convertible into 6.6667 shares of common stock, subject to and contingent upon the approval of the Company's stockholders in accordance with the NASDAQ Stock Market Rules. The Company's stockholders approved such conversion on December 19, 2017. The Series C Preferred Stock has no expiration date.
Issuer
ReShape Lifesciences Inc.
CIK 0001371217
Related Parties
1- filerCIK 0001538581
Filing Metadata
- Form type
- 3
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 4:23 PM ET
- Size
- 21.0 KB